Phase 2 trial of montelukast for prevention of pain in sickle cell disease

Cysteinyl leukotrienes (CysLTs) are lipid mediators of inflammation. In patients with sickle cell disease (SCD), levels of CysLTs are increased compared with controls and associated with a higher rate of hospitalization for pain. We tested the hypothesis that administration of the CysLT receptor ant...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Blood Adv
Päätekijät: Field, Joshua J., Kassim, Adetola, Brandow, Amanda, Embury, Stephen H., Matsui, Neil, Wilkerson, Karina, Bryant, Valencia, Zhang, Liyun, Simpson, Pippa, DeBaun, Michael R.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2020
Aiheet:
Clinical Trials and Observations
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7094028/
https://ncbi.nlm.nih.gov/pubmed/32208487
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001165
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia